Back HIV Prevention Pre-exposure (PrEP) CROI 2017: Bacterial Vaginosis Does Not Affect Efficacy of Oral PrEP in Women

CROI 2017: Bacterial Vaginosis Does Not Affect Efficacy of Oral PrEP in Women


Research presented at the Conference on Retroviruses and Opportunistic Infections last month in Seattle found that the efficacy of oral pre-exposure prophylaxis (PrEP) for women was not affected by bacterial vaginosis (BV) -- the overgrowth in the vagina of untypical microbes. The effectiveness of PrEP in the Partners PrEP study was not significantly different in women with and without BV. This rules out BV as a possible cause for the lower effectiveness of oral PrEP in some studies of women compared to studies of men who have sex with men.

[Produced in collaboration with]

However, another study did find that tissue concentrations of the drug tenofovir were lower in women with BV who used a microbicide gel -- corroborating a difference in effectiveness already noticed in the CAPRISA 004 tenofovir gel study.

Studies are now being conducted to find out if BV affected the efficacy of vaginal rings.

Vaginal Bacteria Not Related to Oral PrEP Effectiveness

Renée Heffron from the University of Washington in Seattle presented the results of an analysis of the effectiveness of oral PrEP in the Partners PrEP study.

Partners PrEP, which announced its results in 2011, recruited 4758 male-female couples in which one partner was HIV positive. The HIV-negative partner was female in 38% of the couples.

Partners PrEP used both tenofovir alone and tenofovir/emtricitabine (the drugs in Truvada) as PrEP and these were compared with a placebo. In women, the effectiveness of tenofovir in preventing infections relative to placebo was 71% and the effectiveness of tenofovir/emtricitabine was 66% (not a significant difference).

In the present study, vaginal cultures were compared between the women who became infected with HIV and 1470 of the 1785 HIV-negative women who did not. Cultures were taken once a year in the 3-year study.

Effectiveness was compared between women who had a Nugent score indicating normal vaginal bacteria and a score indicating BV. The Nugent score rates BV on a scale of 0-10, with 0-3 indicating normal vaginal flora, typified by the dominance of genera such as Lactobacillus, and 7-10, which is defined as BV, and is typified by the dominance of genera such as Gardnerella. Subanalyses were done in 107 women on the specific types of bacteria found, and they correlated well with Nugent scores.

At baseline in this study, 64% of women had a Nugent score of 0-4, 12% had a score of 5-6, and 24% had a score of 7-10.

HIV incidence was compared between women taking placebo and the average effectiveness in women on tenofovir or tenofovir/emtricitabine. In women with Nugent scores of 7-10, PrEP effectiveness was 77% -- actually higher than average, though not significantly so. Incidence in women with BV on placebo was 3.5% a year, and in women with BV on PrEP 0.9% a year.

In women with Nugent scores of 0-4, effectiveness was 73% (annual incidence on placebo 2.5% and on PrEP 0.6%). In women with intermediate scores, effectiveness was 63% -- not significantly different.

In the subset of women whose bacterial types were analyzed, effectiveness in women with Gardnerella types was 69%. It was 70% effective in women with Lactobacillus types, and 74% effective in women without Lactobacillus (this is relevant as Lactobacillus may be protective against some sexually transmitted infections).

Results were no different if women were taking the antibiotic metronidazole, which is often prescribed for BV.

Tenofovir Concentrations in Microbicide Users

In a second study, however, Sharon Hillier from the University of Pittsburgh did find a correlation between BV and lower tissue concentrations of tenofovir in women who used a topical tenofovir vaginal gel.

An analysis of the CAPRISA 004 microbicide study presented at last year’s International AIDS Conference in Durban found a significant difference in the effectiveness of the microbicide gel according to the presence or absence of different bacteria.

Overall, in that study the tenofovir gel was barely effective overall (39% fewer infections in women using it versus placebo). However, among women in whom Lactobacillus were dominant it had 61% effectiveness, and this was highly significant. Conversely, among women in whom non-Lactobacillus types were dominant, it was only 18% effective, which was statistically indistinguishable from zero.

This result may have been complicated, however, by the fact that women with BV tend to have more sex -- it’s one of the causes of it. So the study looked at whether BV bacteria really do affect drug concentrations in the vaginal mucous membrane (epithelium).

This was a secondary analysis of FAME-04, a Phase 1 safety study comparing vaginal film and gel formulations of tenofovir which was presented at last year’s CROI. A total of 41 women were included in this substudy, with an average age of 28. As a safety study, this was not done in a high-risk population: 71% were white women.

Tenofovir levels were compared between women with BV bacterial species and those without, both after 7 days of microbicide gel or film use at home, and subsequently after a single application at the trial center. Drug levels were compared in vaginal fluid after the 7 days, and in cervical biopsies in the center.

In vaginal fluid, the researchers found a significant correlation between higher levels of non-Lactobacillus bacteria and lower tenofovir levels. They also found a marginally significant relationship with the levels seen in blood samples.

There was a much stronger positive correlation between the presence of Lactobacillus bacteria and tenofovir levels in both vaginal fluid and blood samples. In particular, women with no Lactobacillus were more likely to have undetectable levels of tenofovir.

Similarly strong relationships were found after a single dose in the laboratory: the presence of BV-associated bacteria were associated with lower drug levels in cervical tissue and blood plasma after this one dose, and the presence of Lactobacillus with high levels (though not all species: the crispatus, jensenii, and gasseri species were associated with high levels, but Lactobacillus iners was not). Low Nugent score was also associated with high tenofovir levels, particularly in blood plasma.

This study provides direct biological evidence, supporting the CAPRISA 004 findings, that BV bacteria may affect tenofovir blood and tissue levels during topical microbicide use. Hillier suggested a possible mechanism: the inflammation caused by BV bacteria may be turning tenofovir into adenine, the non-active "base" compound it is designed to imitate.

Although this study does find a link between BV and tenofovir levels, it does not directly prove that these impact on the efficacy of topical PrEP. Hiller said that substudies of tenofovir levels were ongoing in the ASPIRE vaginal ring study to find out more.



R Heffron, RS McClelland, J Balkus, et al. Daily oral PrEP is effective among women with abnormal vaginal microbiota. Conference on Retroviruses and Opportunistic Infections. Seattle, February 13-16, 2017. Abstract 85.

SL Hillier, LA Meyn, K Bunge, et al. Impact of vaginal microbiota on genital tissue and plasma concentrations of tenofovir. Conference on Retroviruses and Opportunistic Infections. Seattle, February 13-16, 2017. Abstract 86LB.